Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly results beat expectations and the company raised its outlook, with a large revenue backlog and expected customer prepayments drawing attention. Bulls say strong AI-compute demand and contract-backed funding ease financing concerns, while bears remain focused on heavy debt, interest costs and capital spending; the share reaction has been muted despite the upbeat results.

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy dominates discussion, with traders parsing managements comments on labeling and launch readiness as possible signs of approval. Optimism about the drugs prospects and cardiac data is countered by concerns that approval is uncertain and the decision could bring a sharp downside; the earnings report and a dispute with NS Pharma are secondary topics.

Netlists Q3 results and earnings call are driving attention, with traders focused on Samsung licensing revenue, improving profitability and margins, and expected recurring Micron payments and stronger product sales ahead. Bullish reactions emphasize the stronger financial outlook, while skeptics point to lower quarter-over-quarter product sales and the lack of confirmed SK Hynix or Nasdaq updates; speculation about a Hynix deal remains unconfirmed.

Rigettis Q3 results missed expectations, prompting concern about weak revenue, ongoing losses, and a long path to commercialization. Bears question the valuation of a pre-revenue quantum-computing business, while bulls argue that technical progress and the sectors long-term potential matter more than current financials.

Nvidias selloff is focused on the board investigation into CEO Jensen Huangs acknowledged affair with an executive alleged to have ties to Chinese intelligence, and speculation about possible disclosure or export-control risks; the claims of compromised company secrets remain unsubstantiated. Traders are divided between viewing the controversy and potential leadership risk as grounds for further downside and treating the decline as a buying opportunity because they believe Nvidias AI business remains strong.

LightPaths quarterly results are driving attention: revenue came in below expectations, while earnings per share beat and the company reported a record backlog and improved gross margins. Traders are split between viewing backlog growth and supply-chain recovery as evidence of strong execution and worrying that delayed deliveries and the revenue miss undermine the growth story.

Amprius quarterly report is driving attention: revenue growth and raised full-year revenue guidance were offset by an earnings-per-share miss and weaker-than-expected EBITDA guidance, prompting a sharp selloff. Traders are divided between viewing the drop as an overreaction to the narrow miss and worrying about profitability, cash burn, and dilution risk.

Costcos declared special cash dividend and renewed stock-buyback authorization are driving attention, with traders welcoming the large payout while noting the share price adjusts for the dividend on the ex-date. The reaction is broadly upbeat, though some remain focused on Costcos premium valuation and caution that the dividend is not free money.

Kuras Q3 results and call have focused attention on growing KOMZIFTI use, with traders highlighting higher prescriptions and patient starts and praising managements defense of the drugs position against J&J competition. The reaction is broadly encouraged by the launch momentum, though some traders are concerned about a stock issuance and debate how competitive J&Js data may prove.

NextNavs quarterly results are drawing attention after an earnings-per-share beat and year-over-year revenue growth. Traders are divided on whether the results matter: some welcome the improvement, while others say the stocks longer-term case still hinges on FCC action on its proposed spectrum reconfiguration.